VERTANICAL Receives First European Marketing Authorization for Exilby® as a First-in-Class Non-Opioid Treatment for Chronic Low Back Pain - Pivotal U.S. Phase 3 trial underway

VERTANICAL today announced that Exilby ® (VER-01) has received marketing authorization in Germany for the treatment of chronic low back pain with a radicular (neuropathic) component. The…